Determining and using the most effective and safest treatment is of great importance in cancer disease management. Recently, a potential biomarker has been identified in immunotherapy: tumor mutational burden (TMB), an assessment of the number of relevant mutations in a tumor.
Download this free poster to learn about how we characterized a panel of reference materials for the assessment, harmonization, and improvement of TMB measurements by NGS assays.
Offered Free by: SeraCare
See All Resources from: SeraCare